Sionna Therapeutics is eyeing a $156 million IPO as the cystic-fibrosis-focused biotech looks to take its lead candidate into ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the Nasdaq this year, raising $275 million and $140 million, respectively.

Notably, Metsera (MTSR, NC), an emerging player in the obesity market, saw its stock soar by 47% on its first trading day. Merger and acquisition (M&A) activities in the biotech space were few but ...

Notably, Metsera (MTSR, NC), an emerging player in the obesity market, saw its stock soar by 47% on its first trading day. Merger and acquisition (M&A) activities in the biotech space were few but ...

Last September, another obesity-focused biotech, BioAge, completed an upsized IPO that raised $198 million, after the number of shares on offer was hiked by 40%. Metsera's lead asset is MET-097i ...

Digital health firms in the city raised $4 billion in 2024, up 60% from the previous year, according to a report released ...

President Trump’s first term was bad,” he said, “but nobody knows what’s coming. … This is truly nationalism at its worst, because he won on the campaign [largely] to protect American jobs, claiming ...